LifeSprout is developing the next-generation of synthetic soft tissue substitutes for aesthetic and oncologic restoration.
Intelligent Implants enhance, directs and monitors bone growth in real-rime using wireless implantable electronics.
Barostitch is a first-of-its-kind medical device for the minimally invasive, no-touch closure of calcified, large-bore femoral artery access sites following structural heart interventions.
In conjunction with the Grand Opening of the Center for Device Innovation (CDI @ TMC) in the Fall 2017, Johnson & Johnson Innovation and Johnson & Johnson Medical Devices have launched the CDI @ TMC QuickFire Challenge, a device-focused challenge aimed at game-changing early-stage medical device innovations across strategic areas of interest for Johnson & Johnson Medical Devices, with an emphasis on Surgical Oncology and/or Obesity.
Johnson & Johnson Innovation will award a grant up to $50,000 to the top solutions, one year of paid lab space at JLABS @ TMC in Houston, Texas, including access to the device prototyping lab, and mentorship and coaching from Johnson & Johnson Medical Devices experts including the world renowned Billy Cohn. Additionally, Johnson & Johnson Innovation has partnered with angelMD, an investment platform and marketplace connecting innovative medical startups, physicians, investors, and industry partners to provide the winning solution an additional $100,000 investment from its catalyst fund, plus angelMD will feature the top finalists on its web platform for syndicate partners to invest up to an additional $250,000.
Applications open Tuesday, April 25 and the deadline to apply is Wednesday, June 28, 2017. Winners will be announced at The MedTech Conference in San Jose, CA September 25-27, 2017.
Rewards and benefits
- *in grants for multiple winners
- Entrance to an available JLABS
- Mentoring & Coaching
QuickFire Challenge innovation focus areas
This QuickFire Challenge is looking for companies with a focus on Surgical Oncology and / or Obesity, however, other device companies that align with strategic areas of interest for Johnson & Johnson Medical Devices will be considered. Areas of interest include:
Surgical Oncology - Improved treatment options with reduced complications and better outcomes, Minimally invasive procedures
Obesity - More durable interventions across the continuum, Prevent or reduce morbidities of obesity
Osteoporosis - Minimize OP fracture rate, improve healing and address fragile bone
Osteoarthritis - Early interventions to prevent progression, Better surgical outcomes in advanced disease
Cardiovascular - Durable, effective interventions to improve outcomes in AFIB and structural heart conditions (e.g. CHF)
Why this challenge matters to us
The Johnson & Johnson Medical Devices have a successful history in creating new markets, delivering breakthrough innovation and establishing strong partnerships built on a shared vision. We believe a good idea can come from anywhere, and it’s our goal to break through the noise of the crowded device landscape and find new and innovative technologies that provide minimally invasive solutions to patients.
Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:
- Potential to impact healthcare outcomes in a strategic area of interest
- Uniqueness of solution & level of competition in current market
- Quality & feasibility of technology
- Team credibility & capabilities
- Clarity of plan: Milestones & defined go/no go decisions
About Johnson & Johnson Innovation, JLABS
Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.
JLABS currently has nine locations in innovation hot spots across North America and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco. JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto and a new JLABS @ NYC (in collaboration with the New York Genome Center -opening in 2018). For more information about JLABS, please visit www.jlabs.jnjinnovation.com.
About Johnson & Johnson Medical Devices
Making significant contributions to surgery for over a century, the Johnson & Johnson Medical Devices Companies are in the business of reaching more patients and restoring more lives. We represent the most comprehensive surgical technology and specialty solutions business worldwide, offering an unparalleled breadth of products, services, programs and research and development capabilities directed at advancing patient care while delivering clinical and economic value to health care systems.
About the Center for Device Innovation @ TMC
The Center for Device Innovation @ Texas Medical Center (CDI @ TMC) is a new collaboration (opening mid-2017) that aims to accelerate end-to-end development of breakthrough medical devices. CDI @ TMC will include multiple components to accelerate new medical technologies from concept through commercialization, including a medical device engineering studio housed at the TMC Innovation Institute. This state-of-the-art “maker space” will be home to R&D staff of the Johnson & Johnson Medical Devices Companies and will be used to accelerate both select internal projects and strategically aligned ventures of Johnson & Johnson Medical Devices.
angelMD is an investment platform and marketplace connecting innovative medical startups, physicians, investors, and industry partners. Leading physicians from all over the US have joined the angelMD Scientific Advisory Board and Leaders Club to help source, evaluate and advise companies in biotechnology, medical device and healthcare technology. For more information, visit www.angelmd.co.